Evaluation of Acacia Gum on Microbiome and Bowel Function in Participants With Chronic Constipation
Primary Purpose
Constipation
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
acacia gum
Sponsored by
About this trial
This is an interventional basic science trial for Constipation focused on measuring Acacia gum, gummi arabicum, microbiome, short chain fatty acids, SCFA, stool frequency, stool consitency
Eligibility Criteria
Inclusion Criteria:
- Healthy subjects without clinical diagnosed diseases with relevant effect on the gastrointestinal system or on visceral motility
- Constipation defined as an average of 2 - 3 stools per week (which needs to be confirmed during a prospective run-in phase)
At least one of the following criteria:
- straining during more than 25% of defecations
- lumpy or hard stools (Bristol Stool Form Scale 1 or 2) present more than 25% of defecations
- sensation of incomplete evacuation in more than 25% of defecations
- sensation of anorectal obstruction/ blockage in more than 25% of defecations
- manual manoeuvre to facilitate more than 25% of defecations (such as digital evacuation or support from pelvic floor)
- Criteria of constipation for at least the previous 3 months
- BMI 18.5 - 30 kg/m2
- Stable body weight (+/- 5%) in the last 3 months (self-reported)
- Willing to maintain normal background dietary habits & physical activity levels throughout the study period
- Written consent to participate in the study
Exclusion Criteria:
- Relevant history or presence of any severe medical disorder, potentially interfering with this study in the investigator's judgement (e.g. mal absorption, food intolerance or allergy, chronic gastro-intestinal diseases (e.g. Morbus Crohn, Colitis Ulcerosa), chronic kidney or liver disease, severe depression, immunological disorders, severe cardiovascular disease, diabetes, acute malignant disease within last 3 years except basal cell carcinoma of the skin)
- Prior abdominal surgery which may present a risk for the subject or confound the study results (according to the investigator's opinion)
- Currently (or in the last 3 months) suffering from significant stress, anxiety or depression which, in the subjects opinion, interferes with normal daily life (e.g. has the subject missed days of work due to these conditions) and/or which could be responsible for gastrointestinal problems
- Exclusively vegan or vegetarian diet (high fiber content)
- Regular laxative use at least once per week
- Use of hypolipidaemic drugs (e.g. statins, fibrates, resins, ezetimibe, niacin)
- Subject under prescription for medication or taking dietary supplements possibly interfering with this study (such as anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries, use of PPIs, bismuth salts and/or H2-antagonists, fibers etc.) within 2 weeks prior to study start or during the study; Stable medication (more than 3 months) for hypertension or thyroid gland is allowed.
- Use of pre- and probiotic supplements
Subjects consuming
- food or drinks claimed as 'probiotic', or 'prebiotic more than once weekly
- food or drinks claimed as 'rich in fiber' (including specific milk products) more than 3 times per week
- more than 3 portions of fruits and vegetables (sum) per day
- Smoker
- Intake of antibiotics in the last 4 weeks
- Pregnancy or breastfeeding (also exclude recent pregnancy in the last 3 months). A pregnancy test will be conducted during screening and visits 1 - 3.
- Currently or recently (within 3 months of study entry) taking any medication, which in the opinion of the investigator, could interfere with the outcome of the study, e.g. opioids, anti-psychotics
Sites / Locations
- BioTeSys GmbH
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
acacia gum
Arm Description
Outcomes
Primary Outcome Measures
Gut microbiota
Composition and diversity (Shannon index), Lactobacillogenic and bifidogenic level, Distribution of bacterial taxa at the phylum, family and genus level, Shifts of specific bacterial taxa
Secondary Outcome Measures
Stool frequency
frequency per week will be assessed via diary
Stool consitency
consistency will be assessed via Bristol Stool Form Scale
Gastrointestinal symptoms
Global Gastrointestinal Discomfort Assessment (PAC-SYM), single gastrointestinal symptoms (flatulence, rumbling (i.e. borborygmi)), layative use
Blood biomarker
Lipid profile (total, HDL- and LDL- cholesterol and triglycerides) Blood glucose Electrolytes and minerals (plasma sodium, potassium and calcium) SCFA (short chain fatty acids) (optional) Cytokines: IL-10 & IL-6 (optional)
Stool biomarker
SCFA (short chain fatty acids) Zonulin Calprotectin (optional) Secretory IgA (optional) Beta-defensin (optional) Bile acids (optional) Nitric oxide (optional)
Full Information
NCT ID
NCT04382456
First Posted
May 7, 2020
Last Updated
January 11, 2021
Sponsor
Alpinia Laudanum GmbH
Collaborators
BioTeSys GmbH
1. Study Identification
Unique Protocol Identification Number
NCT04382456
Brief Title
Evaluation of Acacia Gum on Microbiome and Bowel Function in Participants With Chronic Constipation
Official Title
An Exploratory Pilot Study to Evaluate the Impact of Alpinia Acacia Gum on Microbiome and Bowel Function in Subjects With Chronic Constipation
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
June 1, 2020 (Actual)
Primary Completion Date
September 7, 2020 (Actual)
Study Completion Date
September 7, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alpinia Laudanum GmbH
Collaborators
BioTeSys GmbH
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Proof of concept study to investigate the impact of a food supplement consisting of Acacia gum on changes of gut microbiota and production of short chain fatty acids. Additionally, safety, tolerability and parameters of bowel function (stool frequency, stool consistency and gastrointestinal symptoms) will be assessed during the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
Acacia gum, gummi arabicum, microbiome, short chain fatty acids, SCFA, stool frequency, stool consitency
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
acacia gum
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
acacia gum
Intervention Description
Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
Primary Outcome Measure Information:
Title
Gut microbiota
Description
Composition and diversity (Shannon index), Lactobacillogenic and bifidogenic level, Distribution of bacterial taxa at the phylum, family and genus level, Shifts of specific bacterial taxa
Time Frame
day 1, day 43 and day 71
Secondary Outcome Measure Information:
Title
Stool frequency
Description
frequency per week will be assessed via diary
Time Frame
day -14 (run-in phase) until day 70 (end of follow up)
Title
Stool consitency
Description
consistency will be assessed via Bristol Stool Form Scale
Time Frame
day -14 (run-in phase) until day 70 (end of follow up)
Title
Gastrointestinal symptoms
Description
Global Gastrointestinal Discomfort Assessment (PAC-SYM), single gastrointestinal symptoms (flatulence, rumbling (i.e. borborygmi)), layative use
Time Frame
day -14 (run-in phase) until day 70 (end of follow up)
Title
Blood biomarker
Description
Lipid profile (total, HDL- and LDL- cholesterol and triglycerides) Blood glucose Electrolytes and minerals (plasma sodium, potassium and calcium) SCFA (short chain fatty acids) (optional) Cytokines: IL-10 & IL-6 (optional)
Time Frame
day 1, day 43 and day 71
Title
Stool biomarker
Description
SCFA (short chain fatty acids) Zonulin Calprotectin (optional) Secretory IgA (optional) Beta-defensin (optional) Bile acids (optional) Nitric oxide (optional)
Time Frame
day 1, day 43 and day 71
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy subjects without clinical diagnosed diseases with relevant effect on the gastrointestinal system or on visceral motility
Constipation defined as an average of 2 - 3 stools per week (which needs to be confirmed during a prospective run-in phase)
At least one of the following criteria:
straining during more than 25% of defecations
lumpy or hard stools (Bristol Stool Form Scale 1 or 2) present more than 25% of defecations
sensation of incomplete evacuation in more than 25% of defecations
sensation of anorectal obstruction/ blockage in more than 25% of defecations
manual manoeuvre to facilitate more than 25% of defecations (such as digital evacuation or support from pelvic floor)
Criteria of constipation for at least the previous 3 months
BMI 18.5 - 30 kg/m2
Stable body weight (+/- 5%) in the last 3 months (self-reported)
Willing to maintain normal background dietary habits & physical activity levels throughout the study period
Written consent to participate in the study
Exclusion Criteria:
Relevant history or presence of any severe medical disorder, potentially interfering with this study in the investigator's judgement (e.g. mal absorption, food intolerance or allergy, chronic gastro-intestinal diseases (e.g. Morbus Crohn, Colitis Ulcerosa), chronic kidney or liver disease, severe depression, immunological disorders, severe cardiovascular disease, diabetes, acute malignant disease within last 3 years except basal cell carcinoma of the skin)
Prior abdominal surgery which may present a risk for the subject or confound the study results (according to the investigator's opinion)
Currently (or in the last 3 months) suffering from significant stress, anxiety or depression which, in the subjects opinion, interferes with normal daily life (e.g. has the subject missed days of work due to these conditions) and/or which could be responsible for gastrointestinal problems
Exclusively vegan or vegetarian diet (high fiber content)
Regular laxative use at least once per week
Use of hypolipidaemic drugs (e.g. statins, fibrates, resins, ezetimibe, niacin)
Subject under prescription for medication or taking dietary supplements possibly interfering with this study (such as anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries, use of PPIs, bismuth salts and/or H2-antagonists, fibers etc.) within 2 weeks prior to study start or during the study; Stable medication (more than 3 months) for hypertension or thyroid gland is allowed.
Use of pre- and probiotic supplements
Subjects consuming
food or drinks claimed as 'probiotic', or 'prebiotic more than once weekly
food or drinks claimed as 'rich in fiber' (including specific milk products) more than 3 times per week
more than 3 portions of fruits and vegetables (sum) per day
Smoker
Intake of antibiotics in the last 4 weeks
Pregnancy or breastfeeding (also exclude recent pregnancy in the last 3 months). A pregnancy test will be conducted during screening and visits 1 - 3.
Currently or recently (within 3 months of study entry) taking any medication, which in the opinion of the investigator, could interfere with the outcome of the study, e.g. opioids, anti-psychotics
Facility Information:
Facility Name
BioTeSys GmbH
City
Esslingen
ZIP/Postal Code
73728
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Acacia Gum on Microbiome and Bowel Function in Participants With Chronic Constipation
We'll reach out to this number within 24 hrs